Prospective Evaluation of a Fractional 675-nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV
Issued Date
2025-01-01
Resource Type
ISSN
01968092
eISSN
10969101
Scopus ID
2-s2.0-105025215019
Journal Title
Lasers in Surgery and Medicine
Rights Holder(s)
SCOPUS
Bibliographic Citation
Lasers in Surgery and Medicine (2025)
Suggested Citation
Nisagornsen P., Thongjaroensirikul P., Nokdhes Y., Bhorntarakcharoen W., Sittiwanaruk S., Li J.B., Manuskiatti W. Prospective Evaluation of a Fractional 675-nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV. Lasers in Surgery and Medicine (2025). doi:10.1002/lsm.70085 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113699
Title
Prospective Evaluation of a Fractional 675-nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Energy-based treatments for atrophic acne scars (AAS) in darker skin phototypes must balance efficacy with pigmentary safety. While the nonablative 675-nm laser has shown promise with minimal risk of adverse effects, prospective data in Asian populations remain limited. This study evaluated the efficacy, tolerability, and safety of a 675-nm laser for AAS in Fitzpatrick skin types (FSTs) III–IV. Methods: Sixteen adults with AAS underwent 3 monthly sessions using sequential Moveo (low-fluence scanning) and Standard (fractional stamping) modes. Outcomes were assessed at baseline and at 1, 3, and 6 months after the final session, including Goodman and Baron quantitative scores (GBQGASGS), Antera® 3D imaging device, patient satisfaction, procedural pain, and adverse events. Results: GBQGASGS improved by 14.5% at 6 months after the final treatment (19.81 ± 7.31 to 16.94 ± 7.18; p = 0.001), with a 9.7% reduction evident 1 month after the second session (p = 0.017). Antera® 3D analysis demonstrated improvements in skin texture (12.91 ± 4.25 to 11.38 ± 3.97; p = 0.002) and scar volume (2.54 ± 1.33 to 2.04 ± 1.26; p = 0.001). At 6 months, blinded evaluators reported ≥ 25% improvement in 50% of subjects, while 69% of patients reported ≥ 25% improvement. Adverse events were of low incidence and transient in nature, and no serious complications occurred. Conclusions: The 675-nm laser demonstrated significant and sustained improvements in acne scar metrics in Asian patients with FST III–IV, supporting its role as a pigment-safe, nonablative option for atrophic acne scars in skin of color. Trial Registration: Thai Clinical Trials Registry: TCTR20250218009.